The FDA is positioning Lipfendra as a prominent example of its CNPV pilot, while Merck & Co. is mapping out a longer-term strategy for what could become the first PCSK9 pill.
The development comes as the PCSK9 cholesterol drug class continues to face a difficult commercial narrative. Once regarded as a major pharmaceutical opportunity, the class has struggled to match the expectations created by its early promise.
Merck’s focus on a long-term path for an oral PCSK9 treatment places the company at the center of efforts to reshape the category. The FDA’s attention to Lipfendra through the CNPV pilot adds another important dimension to the drug’s development story.
Together, the regulatory spotlight and Merck’s plans underline the ongoing effort to establish a stronger future for PCSK9 medicines despite their history of disappointing commercial performance.
